company background image
TARA logo

Protara Therapeutics NasdaqGM:TARA Stock Report

Last Price

US$4.56

Market Cap

US$50.8m

7D

11.8%

1Y

17.2%

Updated

29 Feb, 2024

Data

Company Financials +

Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$50.8m

TARA Stock Overview

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

TARA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Protara Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Protara Therapeutics
Historical stock prices
Current Share PriceUS$4.56
52 Week HighUS$4.95
52 Week LowUS$1.04
Beta1.7
1 Month Change70.15%
3 Month Change217.77%
1 Year Change17.22%
3 Year Change-66.84%
5 Year Changen/a
Change since IPO-84.80%

Recent News & Updates

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Dec 16
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Recent updates

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Dec 16
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Apr 22
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

The Prognosis For Protara Therapeutics

Oct 13

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Mar 21
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Aug 17
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Protara trades higher as H.C. Wainwright highlights potential of lead asset

Jun 04

Shareholder Returns

TARAUS BiotechsUS Market
7D11.8%1.0%0.4%
1Y17.2%9.2%24.9%

Return vs Industry: TARA exceeded the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: TARA underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is TARA's price volatile compared to industry and market?
TARA volatility
TARA Average Weekly Movement14.7%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: TARA's share price has been volatile over the past 3 months.

Volatility Over Time: TARA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a25Jesse Sheffermanhttps://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.

Protara Therapeutics, Inc. Fundamentals Summary

How do Protara Therapeutics's earnings and revenue compare to its market cap?
TARA fundamental statistics
Market capUS$50.80m
Earnings (TTM)-US$69.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TARA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$69.17m
Earnings-US$69.17m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.09
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TARA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.